New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
07:15 EDTMGNXMacroGenics initiates Phase 1 study of MGD006
MacroGenics announced that a first patient received drug in a Phase 1 study of MGD006 in relapsed or refractory acute myeloid leukemia. MGD006 is a humanized, Dual-Affinity Re-Targeting, or DART, bi-specific antibody-based molecule that binds to both CD123 and CD3, antigens expressed on leukemic cells and T lymphocytes, respectively. This study marks the first clinical trial of a DART product candidate.
News For MGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
09:22 EDTMGNXMacroGenics added to Focus List at Roth Capital
Subscribe for More Information
December 7, 2014
14:10 EDTMGNXAmerican Society of Hematology to hold a meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use